AACR 2025 preview – new preclincal approaches abound
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
Xilio gets a Gilead-shaped reprieve
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.
